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Abstract
Background: Systemic sclerosis (SSc; scleroderma) is an uncommon autoimmune rheumatic disease characterised
by autoimmunity, vasculopathy and fibrosis. Gene expression profiling distinguishes scleroderma from normal skin,
and can detect different subsets of disease, with potential to identify prognostic biomarkers of organ involvement
or response to therapy. We have performed gene expression profiling in skin samples from patients with limited
cutaneous SSc (lcSSc).
Methods: Total RNA was extracted from clinically uninvolved skin biopsies of 15 patients with lcSSc and 8 healthy
controls (HC). Gene expression profiling was performed on a DNA oligonucleotide microarray chip. Differentially
expressed genes (DEG) were identified using significance analysis of microarrays (SAM). Functional enrichment
analysis of gene signatures was done via g:Profiler.
Results: There were 218 DEG between lcSSc and HC samples (false discovery rate <10%): 181/218 DEG were
upregulated in lcSSc samples. Hierarchical clustering of DEG suggested the presence of two separate groups of
lcSSc samples: “limited 1” and “limited 2”. The limited-1 group (13 samples, 10 unique patients) showed
upregulation of genes involved in cell adhesion, cardiovascular system (CVS) development, extracellular matrix and
immune and inflammatory response. The CVS development signature was of particular interest as its genes showed
very strong enrichment in response to wounding, response to transforming growth factor (TGF)-β and kinase
cascade. Neither limited-2 samples (six samples, five unique patients) nor HC samples showed functional
enrichment. There were no significant differences in demographic or clinical parameters between these two
groups. These results were confirmed using a second independent cohort.
Conclusions: Our study suggests the presence of molecular subsets in lcSSc based on gene expression profiling of
biopsies from uninvolved skin. This may reflect important differences in pathogenesis within these patient groups.
We identify differential expression of a subset of genes that relate to CVS and are enriched in fibrotic signalling. This
may shed light on mechanisms of vascular disease in SSc. The enrichment in profibrotic profile suggests that
dysregulated gene expression may contribute to vasculopathy and fibrosis in different disease subsets.
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Background
Systemic sclerosis (SSc; scleroderma) represents a major
clinical challenge and offers insight into fundamental
processes relating to autoimmunity, fibrosis and vascular
injury and pathology. It is an uncommon immune-
mediated rheumatic disease with a very high clinical bur-
den, high mortality and limited treatment options [1, 2]
and provides a model for more common forms of organ-
based fibrosis in the lung, liver and kidney. Recent ob-
servational cohort studies have highlighted remarkable
clinical diversity in terms of pattern and extent of skin
and internal organ involvement, clinical outcome and re-
sponse to therapy [3–5]. Most current and emerging
treatment strategies focus on intensive immunosuppres-
sion though greater understanding of the biology of dis-
ease outcomes, in particular mechanisms that determine
improvement in skin and organ-based disease, may help
to personalize treatment strategies more effectively [6].
The limited cutaneous subset of SSc (lcSSc) is charac-
terised by less severe and extensive skin fibrosis but pa-
tients can develop major internal organ complications
and the vascular manifestations of SSc, particularly pul-
monary arterial hypertension and digital ulceration, are
prominent in this subset [3]. Detailed gene expression
analysis in SSc biopsies has recently been used to define
molecular intrinsic subsets of the disease and to provide
mechanistic insight into the pathobiology [7–14]. Inter-
estingly, clinically uninvolved skin in the more extensive
diffuse cutaneous subset of SSc has closely replicated
gene expression signatures compared with biopsies from
clinically involved skin [7] and a number of vasoactive
genes have been identified in this way in skin from pa-
tients with the limited subset, who cluster separately from
healthy controls and from patients with diffuse disease [7].
It has been shown that lesional and non-lesional lcSSc bi-
opsies consistently cluster together and show concordance
in their deregulated pathways [7, 14]. The numbers of
patients with limited disease in those studies are small
but the results are consistent. On this basis we sought to
develop greater understanding about the gene expression
abnormalities in the more prevalent lcSSc subset through
detailed transcriptional analysis of skin biopsies taken
from uninvolved forearm skin. We hypothesise that this
may give valuable insight into the key pathogenetic pro-
cesses underlying the disease and also provide potential
for defining and characterising molecular subsets of lcSSc.
Since the molecular subsets of SSc may also inform clin-
ical decision-making and treatment selection, there may
be additional value from extending this concept more
broadly into lcSSc.
In this study, we demonstrate differential gene expres-
sion in a cohort of lcSSc patients and healthy controls
and describe a distinct lcSSc subgroup not identifiable
by clinical or serological assessment showing enrichment
in cell adhesion, cardiovascular system (CVS) develop-
ment and extracellular matrix genes. We confirm our
findings in a second independent cohort of samples. The
CVS development signature was significantly different
between both subgroups of limited patients and a con-
trol group.
Methods
Inclusion criteria and study participants
Demographic information, clinical history including organ
involvement, other diagnoses and extent of skin involve-
ment, autoantibody profiles and treatments were retrieved
from medical notes or obtained at the time of skin biopsy.
Diagnosis of SSc was made according to the 2013 Ameri-
can College of Rheumatologists (ACR)/European League
Against Rheumatism (EULAR) classification criteria and
assignment to the limited cutaneous subset reflected the
distribution and extent of skin thickening at the time of
biopsy together with other typical disease characteristics
[15]. Autoantibodies were measured in an accredited insti-
tutional autoimmune serology laboratory using validated
commercial tests with appropriate quality control and
blinded assessment of the results at the time of biopsy. In
brief, antinuclear antibody (ANA) pattern was screened by
indirect immunofluorescence using an HEp-2 cell sub-
strate and further characterisation of defined extractable
nuclear antigen (ENA) was by counterimmunoelectro-
phoresis for anti-ENA using soluble extracts from human
spleen and rabbit thymus acetone powder (Pelfreez Bio-
logicals, Rogers, AR, USA) as antigen. All patients in-
cluded in this study signed informed consent for their
clinical and laboratory data to be used in this clinical
research project.
Sample collection
Forearm 4-mm skin punch biopsies were performed
both in patients with lcSSc and in healthy controls, and
were stored for extraction in RNAlaterTM RNA stabilisa-
tion reagent (Ambion, Austin, TX, USA) at 4 °C over-
night followed by longer-term storage at -70 °C. To
avoid a potential confounding effect of different degrees
of skin thickening or fibrosis, biopsy sites were selected
from skin that was not clinically involved. There were
no changes in pigmentation or dryness.
Microarray processing
Tissue homogenization was performed using Qiagen
TissueLyser II. RNA purification was carried out in a
QIAcube with Qiagen RNeasy Fibrous Tissue Mini Kit
(Qiagen, Gaithersburg, MD, USA). The Agilent 2100
Bioanalyzer (Agilent, Santa Clara, CA, USA) was used to
assess the RNA integrity of samples with numbers >7.
RNA concentration was measured with Thermo Scientific
NanoDrop 2000 Spectrophotometer (Wilmington, DE,
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USA). A measure of 200 ng of total RNA was amplified
and labelled with Agilent's Quick-Amp Labelling Kit.
Cy3-labelled samples and Cy5-labelled Universal Hu-
man Reference RNA (Stratagene, La Jolla, CA, USA) were
co-hybridized to Agilent's Human Genome (4 × 44 K) Mi-
croarrays (G4112F). Data were log2 lowess-normalised
and filtered for probes with intensity ≥1.5-fold over local
background in Cy3 or Cy5 channels. Data were multiplied
by -1 to convert them to log2(Cy3/Cy5) ratios. Probes with
>20% missing data were excluded.
Gene expression data pre-processing
Expression data were pre-processed using GenePattern
[16] modules with default settings unless stated other-
wise. Missing values were imputed using the ImputeMis-
singValuesKNN module. Expression data were collapsed
from probes to unique genes using the CollapseDataset
module with the Agilent 4 × 44 K chip platform. As mi-
croarrays were processed in three separate batches,
batch bias was adjusted for using GenePattern imple-
mentation of ComBat [17] by means of parametric prior
method and information about lcSSc samples and con-
trols as a covariate. Batch bias was assessed before and
after ComBat using guided principal component analysis
(gPCA) [18]. Expression data were adjusted by median-
centering genes in Cluster 3.0 [19].
Differential expression and functional enrichment analysis
Differentially expressed genes were identified using signifi-
cance analysis of microarrays (SAM) [20]. Two-class un-
paired response type was used for comparing two groups
and multiclass response type was used for comparing
three groups. The number of permutations was set to 500.
Expression data for significantly differentially expressed
genes were hierarchically clustered in Cluster 3.0 and visu-
alized in Java TreeView [21], version 1.1.6r4. Functional
enrichment analysis of gene signatures was done using
g:Profiler [22] with the following settings: maximum size
of functional category was set to 3500, default multiple
testing correction method (g:SCS significance threshold)
was used and regulatory motif and protein-protein inter-
action databases were excluded from the analyses.
Results
Subject selection and clinical characteristics
There were 23 subjects included in the discovery cohort:
15 patients with lcSSc and 8 healthy controls. The study
samples were collected and analysed in two stages, first
in 10 biopsies from patients with lcSSc and from 5
healthy controls that generated the initial CVS signature,
and then in samples from an extended cohort with an
additional 6 patients with lcSSc and 3 healthy controls.
These later samples were collected independently of the
first set of samples.
Demographics, clinical characteristics, organ-based
disease and therapies are listed in Table 1. The demo-
graphics of the control group were broadly similar to
patients in terms of age, sex and ethnicity and these are
also representative of the single-centre cohort that in-
cluded the sample population. All patients had estab-
lished lcSSc with minimum disease duration of 2 years,
and most had had the condition for more than 10 years
at the time of biopsy. Patients included in the study
retained the subset designation according to their early
stage disease and therefore no patients who would previ-
ously have been designated as having ‘diffuse’ SSc or those
who had higher skin scores in the past were included.
Serological findings were again representative of a cohort
of lcSSc patients but kept purposefully broad: six patients
had centromere pattern staining on indirect immunofluor-
escence (IIF) for ANA, and four had scl-70 reactivity. Two
patients had overlap Ro antibodies and two were ANA-
negative; one had serological features of lupus with high
double-stranded (ds) DNA antibodies and low C4. There
were 6/15 patients with digital ulcers at the time of biopsy
and the majority took therapy for a vascular complication,
either for significant Raynaud’s phenomenon or for digital
ulceration. No patients from this cohort had a diagnosis of
pulmonary arterial hypertension and none had had a
scleroderma renal crisis or myositis. Four had interstitial
lung disease and three (more than may be expected) had
an overlap diagnosis of inflammatory arthritis: these two
latter diagnoses resulted in the significant use of immuno-
suppressive medications compared with most cohorts of
lcSSc patients. The broad but characteristic range of clin-
ical and serological features demonstrated in this cohort
allowed us to identify pathogenic factors that may exist at
the gene expression level but that cannot be explained by
standard outpatient assessment.
Overview of gene expression profiles
There were 218 differentially expressed genes (DEG) be-
tween lcSSc and healthy control samples (false discovery
rate (FDR) <10%). Of these 218 genes, 181 (83%) were
upregulated in lcSSc samples and were significantly
enriched in several terms related to the extracellular
matrix (ECM), e.g. ECM organisation and ECM compo-
nent and response to growth factor, tissue development
and regulation of the serine/threonine kinase signalling
pathway. This gene signature included genes previously
implicated in the pathogenesis of SSc such as ANGPT2,
CD163, COMP, CTGF and TIMP2, among others
(Fig. 1a). The full list of significantly differentially
expressed genes is available in Additional file 1.
Even though we specifically asked for genes differentially
expressed between lcSSc samples and healthy controls, 6
lcSSc samples (5 unique patients) clustered with controls,
whereas the remaining 13 lcSSc samples (10 unique
Derrett-Smith et al. Arthritis Research & Therapy  (2017) 19:156 Page 3 of 10
patients) formed a distinct cluster (Fig. 1b). We designated
13 lcSSc samples as the “limited 1” group and 6 lcSSc
samples as the “limited 2” group. The expression of 181
genes significantly upregulated in lcSSc vs. healthy con-
trols was also significantly different in all pairwise compar-
isons between limited 1, limited 2 and control samples
(Fig. 1c). Mean ± standard error of the mean expression
values for 181 gene signatures were as follows: 0.23 ± 0.01
for limited 1, -0.02 ± 0.03 for limited 2 and -0.46 ± 0.03 for
healthy control samples.
Since comparison between lcSSc and controls was
suggestive of the presence of two lcSSc groups, we per-
formed multiclass SAM to identify DEG between
limited-1, limited-2 and healthy control samples: 807
genes were differentially expressed between these three
groups (FDR <10%). Again, limited-2 samples clustered
with controls and separately from the limited-1 group
(Fig. 2; see Additional file 2 for the full gene list).
Genes with significantly increased expression in either
the limited-2 group or in healthy controls were not
functionally enriched. Genes with significantly increased
expression in samples from the limited-1 group (475/807,
58.9%) displayed very strong enrichment in functional
terms related to ECM and vasculature development
(p < 10-10) and strong enrichment in cell adhesion,
response to growth factor, mitogen-activated protein
kinase (MAPK) cascade and response to wounding
(p < 10-5), among others. Enrichment in immune signalling
was comparatively weak (e.g. p = 0.0183 for immune sys-
tem process and p = 0.0208 for inflammatory response).
The entire g:Profiler output is listed in Additional file 3.
For the limited-1 group, the term with the most signifi-
cant functional enrichment was cardiovascular system de-
velopment (p = 3.01 × 10-14): 70 out of 475 genes with
increased expression in limited-1 samples were involved
in this biological process. This set of 70 genes essentially
recaptured many of the biological themes observed in the
bigger limited-1 gene expression signature. For example,
there was very strong enrichment in angiogenesis, re-
sponse to growth factor and cell proliferation (p < 10-10)
Table 1 Demographic, clinical and serological characteristics of lcSSc patients and healthy controls
Control subjects (n = 8) All LcSSc patients (n = 15)
Age, median (range) years 53 (29–70) 62 (28–15)
Sex, N (%) female 4 (50) 12 (80)
Race, N (%) Caucasian 7 (87.5) 10 (100)
MRSS, median (range) 6 (3–10)
Disease duration from first non-Raynaud’s symptom, median (range) years 14 (2–40)
ANA primary pattern, N (%) patients Homogenous 4 (27)
Speckled 2 (13)
Centromere 6 (40)
Nucleolar 1 (7)
SSc-specific antibodies Scl-70 4 (27)
RNA pol III 0
Vasculopathy, N (%) patients Digital ulcers 6 (40)
PAH 0
Renal crisis 0
Interstitial lung disease, N (%) 4 (27)
Inflammatory arthritis, N (%) 3 (20)
Vascular therapies, N (%) patients ARB 10 (66)
Ca channel antagonist 4 (27)
Iloprost 4 (27)
PDE5 inhibitor 3 (20)
Immunosuppressive therapies, N (%) patients PDN 4 (27)
MMF 3 (20)
MTX 2 (13)
AZA 1 (7)
HCQ 3 (20)
ANA antinuclear antibodies, SSc systemic sclerosis, MRSS modified Rodnan skin score, PAH pulmonary arterial hypertension, ARB angiotensin receptor blocker,
PDE cGMP-regulated phosphodiesterase, MTX methotrexate, HCQ hydroxychloroquine, PDN prednisolone, AZA azathioprine
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Fig. 1 (See legend on next page.)
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and strong enrichment in ECM, cartilage development,
MAPK cascade, cell adhesion and response to wounding
(p < 10-5), among others. It was also strongly enriched in
response to transforming growth factor (TGF)-β (p =
2.87 × 10-7, 12/70 genes). Additional file 4 contains the en-
tire g:Profiler output for this analysis. There were no sig-
nificant differences in demographic, clinical or serological
parameters that correlated with limited-1 and limited-2
groups, in particular, the presence of significant micro-
vascular involvement and hallmark antibody reactivities
were similar across each group as shown in Table 2 below.
Validation of microarray gene expression profiles in an
independent lcSSc cohort
We applied the same approach described above to valid-
ate our findings in an independent cohort of patients
with lcSSc derived from an American population (the
Boston University cohort), with samples comprising 24
lcSSc and 4 control samples. Similar to this study
cohort, analysis of differential expression between lcSSc
and control samples suggested the presence of two
subgroups of patients with lcSSc (group 1 with 14 lcSSc
samples and group 2 with 10 lcSSc samples). We then
compared the gene expression of the CVS development
gene signature across subgroups of lcSSc patients and
controls from the validation study. This gene expression
signature was significantly different among both subgroups
of patients with LcSSc and a control group (Fig. 3b), paral-
leling the results from this study (Fig. 3a).
Discussion
In this study we have assessed molecular heterogeneity in
gene expression profiles from skin biopsies taken from un-
involved skin of lcSSc patients compared with matched
healthy controls. We have identified two subgroups within
the lcSSc patient population in this study, which we
termed limited 1 and limited 2. Patients from the limited-
2 subgroup correspond to a third of the lcSSc cases and
are generally characterised by a subtle alteration in gene
expression that resembles but is distinct from the control
samples. The majority of lcSSc cases cluster into a
limited-1 subgroup associated with a substantial number
of genes with significant differential expression, which are
involved in multiple functional terms with known or po-
tential relevance to SSc pathogenesis. We have confirmed
our findings in a second cohort.
Most compelling is the identification of a cardiovascu-
lar system (CVS) development gene expression signa-
ture. This is interesting because of the well-recognised
vascular abnormalities that are seen in lcSSc [3]. The
idea that these pathways may be upregulated or altered
in lcSSc even at sites that are not clinically affected is
notable and may point towards an inherent susceptibility
to vasculopathy that may be a hallmark of SSc. It is
plausible that using uninvolved lcSSc skin we were able
to minimise the impact of pathways reflecting inflamma-
tion and that this may explain the novel findings in our
study. It was reassuring to find that several genes identi-
fied within this group were well-recognised in sclero-
derma pathogenesis, including, for instance, COMP,
THBS1 and CTGF. These have traditionally been consid-
ered as pro-fibrotic markers, but all have a role in the
regulation of vascular function [23–25]. More traditional
“vascular” markers such as MMP19 and COL4A1 were
also included. It is also attractive to consider that recap-
itulation of developmental gene expression programmes
may be central to susceptibility to development of SSc
since it can be envisaged as a disease of perturbed con-
nective tissue repair. There is a strong precedent for the
same genetic pathways and programmes that are used in
embryonic and post-natal growth and development to be
recapitulated in acquired disease [26]. This may also fit
with the model of SSc being a susceptibility genotype
that we have recently postulated for the key complication
of pulmonary arterial hypertension [27].
It is also notable that there were no clear clinical or
serological associations with the molecular subgroups of
lcSSc. This is relevant since it suggests that gene-
expression-based subsets may indeed add to the clinical
and serological factors that are already used in the clinic
to subgroup patients. This would be analogous to the in-
trinsic subsets of diffuse cutaneous SSc (dcSSc) that have
been reported and that are already of clinical utility [7].
Of note, in the cohort from which the study samples
were taken, 40% of patients with limited disease were
anti-topoisomerase (Scl-70)-positive and while this is
traditionally thought to represent diffuse scleroderma,
the patients in this cohort are categorised according to
the distribution of skin disease at an early stage of dis-
ease and retain that subset over the course of their
follow-up period. There were, therefore, no patients in-
cluded in this study who would have experienced
(See figure on previous page.)
Fig. 1 Gene expression in whole skin samples from patients with limited cutaneous systemic sclerosis (lcSSc) and healthy controls (Controls). a
Heatmap: red indicates upregulation, green indicates downregulation. Gene expression in the limited 1 subgroup of samples from patients with
lcSSc differs markedly from both the limited 2 subgroup and from healthy controls, which shared similar gene expression patterns. Sample genes
of interest are listed. b Hierarchical clustering of genes distinguishing lcSSc samples from healthy control samples identifies three distinct clusters,
termed limited 1, limited 2 and healthy control. Norm Normal. c Pairwise comparisons between limited 1, limited 2 and controls. Data are plotted
as mean with SEM values. P values were derived from the Kruskal-Wallis test followed by Dunn's multiple comparisons test
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remission to a low skin score with previous diffuse or
more severe skin disease.
It is striking that many of the genes involved in CVS
development are also seen in other relevant pathways
such as ECM and response to TGF-β. Not only does this
give some key candidate genes and pathways that could
be perturbed in SSc but it also is a reminder that these
factors that have been focussed on for a role in fibrosis
may also have other roles in the biology or the disease.
Thus it is plausible that the patterns of gene expression
are altered in SSc and that this may have distinct conse-
quences depending upon the stage and subset of disease.
Further work will be required to assess whether these
differences in expression reflect susceptibility to SSc that
depends on genetic or epigenetic factors or whether they
are reflective of pathogenetic processes that are occur-
ring within the clinically uninvolved skin in limited SSc.
Strengths of the study include the well-characterised
patients from a single centre, which may reduce the vari-
ability that can be a hallmark of multicentre cohorts and
ensures standard classification and clinical evaluation. In
addition, the use of well-established gene expression ana-
lysis platforms and semi-automated sample processing
minimises technical variation that has been a limitation in
some studies. Inclusion of a matched control group of
healthy individuals was important to allow reliable inter-
pretation of the “limited” gene expression signature.
Weaknesses of the study are the limitations of a rela-
tively small study cohort that may not allow generalis-
ability of our findings. However, the results are in line
with those previously reported for subjects with lcSSc
included in earlier gene expression studies [7]. We have
validated our results in an independent cohort of pa-
tients with consistent findings across all groups. There is
also a risk, given the small size of the study that there
may be confounding effects on gene expression due to
differences in immunosuppressive therapies, as an ex-
ample. There were no statistically significant differences
or strong trends between the limited-1 and limited-2
groups in terms of demographics, clinical history, treat-
ments or serology in our study.
We have not included patients with clinically involved
forearm skin in this study. There are no adequately pow-
ered studies that confirm concordance between clinically
involved and uninvolved skin but previous data do
suggest this; these confirmatory studies are required
to extend and validate our findings further as part of a
Fig. 2 Multiclass significance analysis of microarrays (SAM) between
the three identified clusters. Multiclass SAM was used to identify 807
differentially expressed genes (false discovery rate <10%) between
limited -1, limited -2 and healthy control samples. Sample genes are
listed. The majority of differentially expressed genes (475/807, 58.9%)
had increased expression in the limited-1 group
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larger future study of gene expression in lcSSc. In-
volved distal skin is not biopsied in our patients due
to concerns about wound healing. Finally, both further
post-transcriptomic functional studies, and modern
techniques that allow structural analysis of mRNA ex-
pression most notably to examine the dermal micro-
circulation and perivascular space would localise gene
expression changes and verify that differential gene
expression, particularly from the CVS development
cluster, are reflected by differential protein expression.
Conclusions
We showed that gene expression profiling of biopsies
from uninvolved skin in lcSSc differentiates two potential
Table 2 Clinical and laboratory parameters of the limited-1 and limited-2 subgroups
Clinical feature Limited 1 (n = 10) Limited 2 (n = 5)
MRSS, median (range) 5.5 (3–10) 6 (5 − 7)
Disease duration from first non-Raynaud’s symptom, median (range) years 16 (4–40) 6 (2–28)
ANA primary pattern, N (%) patients Homogenous 3 (30) 1 (20)
Speckled 1 (10) 1 (20)
Centromere 5 (50) 1 (20)
Nucleolar 0 1 (20)
SSc-specific antibodies Scl-70 3 (30) 1 (10)
RNA pol III 0 0
Vasculopathy, N (%) patients Digital ulcers 4 (40) 2 (40)
PAH 0 0
Renal crisis 0 0
Interstitial lung disease, N (%) 2 (20) 2 (40)
Inflammatory arthritis, N (%) 3 (30) 0
Vascular therapies, N (%) patients ARB 8 (80) 2 (40)
Ca channel antagonist 2 (20) 2 (40)
Iloprost 3 (30) 1 (20)
PDE5 inhibitor 1 (10) 2 (40)
Immunosuppressive therapies, N (%) patients PDN 2 (20) 2 (40)
MMF 2 (20) 1 (20)
MTX 2 (20) 0
AZA 1 (10) 0
HCQ 2 (20) 1 (20)
ANA antinuclear antibodies, SSc systemic sclerosis, MRSS modified Rodnan skin score, PAH pulmonary arterial hypertension, ARB angiotensin receptor blocker,
PDE cGMP-regulated phosphodiesterase, MTX methotrexate, HCQ hydroxychloroquine, PDN prednisolone, AZA azathioprine
Fig. 3 Cardiovascular development trends in discovery and validation cohorts. Pairwise comparisons between limited 1, limited 2 and control
samples in the discovery cohort (a) and an independent validation cohort (b). Data are plotted as mean with SEM values. P values were derived
from the Kruskal-Wallis test followed by Dunn's multiple comparisons test. CVS cardiovascular system
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subgroups that overlap with other clinical and serological
features. This may reflect important differences in patho-
genesis within these patient groups. In addition, we identi-
fied differential expression of a subset of genes that relate
to CVS development. Since the lcSSc subset is charac-
terised by vasculopathy in the skin and internal organs,
this may shed light on underlying mechanisms of vascular
disease in SSc. The clinical implications of our findings
will need to be analysed in future larger studies.
Additional files
Additional file 1: Genes significantly differentially expressed between
lcSSc and control groups. Green cells: genes with increased expression in
controls. Yellow cells: genes with increased expression in lcSSc samples.
(XLSX 16 kb)
Additional file 2: Genes significantly differentially expressed between
the limited-1, limited-2 and control groups. Orange cells: genes with
increased expression in limited 1 group. Green cells: genes with increased
expression in controls. Grey cells: genes with increased expression in
limited 2 group. (XLSX 38 kb)
Additional file 3: g:Profiler output for 475 genes with increased
expression in the limited-1 group (multiclass SAM, FDR <10%). Additional
files 3 contain the following column headers. Descriptions are as follows:
p value: significance of enrichment in a given term corrected for multiple
hypothesis testing using default g:GOSt method g:SCS. Q&T: overlap
between genes in the query (Q) and genes in the genome annotated to
a given term (T). t type: term category - Gene Ontology: Biological
Process (BP), Molecular Function (MF), Cellular Component (CC); KEGG
(keg); Reactome (rea). t name: term name. Q&T list: list of genes forming
the overlap between query (Q) and genome lists for a given term (T).
(XLSX 25 kb)
Additional file 4: g:Profiler output for 70 genes with increased expression
in the limited-1 group annotated to cardiovascular system development.
Additional file 4 contains the following column headers. Descriptions are as
follows: p value: significance of enrichment in a given term corrected for
multiple hypothesis testing using default g:GOSt method g:SCS. Q&T:
overlap between genes in the query (Q) and genes in the genome
annotated to a given term (T). t type: term category - Gene Ontology:
Biological Process (BP), Molecular Function (MF), Cellular Component
(CC); KEGG (keg); Reactome (rea). t name: term name. Q&T list: list of
genes forming the overlap between query (Q) and genome lists for a
given term (T). (XLSX 29 kb)
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